Optimised point estimators for multi-stage single-arm phase II oncology trials

References

• Armitage, P. 1957. Restricted sequential procedures. Biometrika 44:9–56. doi:10.1093/biomet/44.1-2.9.
   Web of Science ®Google Scholar
• Chang, M., H. Wieand, and V. Chang. 1989. The bias of the sample proportion following a group sequential phase II clinical trial. Statistics in Medicine 8:563–570. doi:10.1002/sim.4780080505.
   PubMed Web of Science ®Google Scholar
• Chen, T. 1997. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine 16:2701–2711. doi:10.1002/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Collen, C., N. Christian, D. Schallier, M. Meysman, M. Duchateau, G. Storme, and M. De Ridder. 2014. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Annals of Oncology 25:1954–1959. doi:10.1093/annonc/mdu370.
   PubMed Web of Science ®Google Scholar
• Eisenhauer, E., P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, and M. Mooney, et al. 2009. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Englert, S., and M. Kieser. 2015. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials. Statistics in Medicine 34:2128–2137. doi:10.1002/sim.6479.
   PubMed Web of Science ®Google Scholar
• Fairbanks, K., and R. Madsen. 1982. P values for tests using a repeated significance test design. Biometrika 69:69–74.
   Web of Science ®Google Scholar
• Fan, X., D. DeMets, and K. Lan. 2004. Conditional bias of point estimates following a group sequential test. Journal of Biopharmaceutical Statistics 14:505–530. doi:10.1081/BIP-120037195.
   PubMedGoogle Scholar
• Girshick, M., F. Mosteller, and L. Savage. 1946. Unbiased estimates for certain binomial sampling problems with applications. The Annals of Mathematical Statistics 17:13–23. doi:10.1214/aoms/1177731018.
   Google Scholar
• Grayling, M., M. Dimairo, A. Mander, and T. Jaki. 2019. A review of perspectives on the use of randomization in phase II oncology trials. Journal of the National Cancer Institute 111:1255–1262. doi:10.1093/jnci/djz126.
   PubMedGoogle Scholar
• Grayling, M., and A. Mander. 2021. Two-stage single-arm trials are rarely analyzed effectively or reported adequately JCO Precision Oncology 5 1813–1820. doi:10.1200/PO.21.00276 .
   Web of Science ®Google Scholar
• Guo, H., and A. Liu. 2005. A simple and efficient bias-reduced estimator of response probability following a group sequential phase II trial. Journal of Biopharmaceutical Statistics 15:773–781. doi:10.1081/BIP-200067771.
   PubMed Web of Science ®Google Scholar
• Jain, N., E. Curran, N. Iyengar, E. Diaz-Flores, R. Kunnavakkam, L. Popplewell, M. Kirschbaum, T. Karrison, H. Erba, and M. Green, et al. 2014. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A University of Chicago phase II consortium trial. Clinical Cancer Research 20:490–498. doi:10.1158/1078-0432.CCR-13-1311.
   PubMed Web of Science ®Google Scholar
• Jennison, C., and B. Turnbull. 1983. Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics 25:49–58. doi:10.1080/00401706.1983.10487819.
   Web of Science ®Google Scholar
• Jung, S., and K. Kim. 2004. On the estimation of the binomial probability in multistage clinical trials. Statistics in Medicine 23 (6):881–896. doi:10.1002/sim.1653.
   PubMed Web of Science ®Google Scholar
• Jung, S., T. Lee, K. Kim, and S. George. 2004. Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine 23 (4):561–569. doi:10.1002/sim.1600.
   PubMed Web of Science ®Google Scholar
• Koyama, T., and H. Chen. 2008. Proper inference from Simon’s two-stage designs. Statistics in Medicine 27 (16):3145–3154. doi:10.1002/sim.3123.
   PubMed Web of Science ®Google Scholar
• Kunzmann, K., and M. Kieser. 2018. Test-compatible confidence intervals for adaptive two-stage single-arm designs with binary endpoint. Biometrical Journal 60 (1):196–206. doi:10.1002/bimj.201700018.
   PubMed Web of Science ®Google Scholar
• Law, M., M. Grayling, and A. Mander. 2022. A stochastically curtailed single‐arm phase II trial design for binary outcomes Journal of Biopharmaceutical Statistics doi:10.1080/10543406.2021.2009498 . .
   PubMed Web of Science ®Google Scholar
• Lendvai, N., P. Hilden, S. Devlin, H. Landau, H. Hassoun, A. Lesokhin, I. Tsakos, K. Redling, G. Koehne, D. Chung, et al. 2014. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 124 (6):899–906. doi:10.1182/blood-2014-02-556308.
   PubMed Web of Science ®Google Scholar
• Li, Q. 2011. An MSE-reduced estimator for the response proportion in a two-stage clinical trial. Pharmaceutical Statistics 10 (3):277–279. doi:10.1002/pst.414.
   PubMed Web of Science ®Google Scholar
• Liu, A., J. Troendle, K. Yu, and V. Yuan. 2004. Conditional maximum likelihood estimation following a group sequential test. Biometrical Journal 46 (6):760–768. doi:10.1002/bimj.200410076.
   Web of Science ®Google Scholar
• Mander, A., and S. Thompson. 2010. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemporary Clinical Trials 31 (6):572–578. doi:10.1016/j.cct.2010.07.008.
   PubMed Web of Science ®Google Scholar
• Mander, A., J. Wason, M. Sweeting, and S. Thompson. 2012. Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. Pharmaceutical Statistics 11 (2):91–96. doi:10.1002/pst.501.
   PubMed Web of Science ®Google Scholar
• Pepe, M., Z. Feng, G. Longton, and J. Koopmeiners. 2009. Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Statistics in Medicine 28 (5):762–779. doi:10.1002/sim.3506.
   PubMed Web of Science ®Google Scholar
• Porcher, R., and K. Desseaux. 2012. What inference for two-stage phase II trials? BMC Medical Research Methodology 12:117 doi:10.1186/1471-2288-12-117.
   PubMed Web of Science ®Google Scholar
• Schoffski, P., A. Wozniak, S. Stacchiotti, P. Rutkowski, J. Blay, L. Lindner, S. Strauss, A. Anthoney, F. Duffaud, and S. Richter, et al. 2017. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with met alterations: European organization for research and treatment of cancer phase II trial 90101 ‘CREATE’. Annals of Oncology 28 (12):3000–3008. doi:10.1093/annonc/mdx527.
   PubMed Web of Science ®Google Scholar
• Schultz, J., F. Nichol, G. Elfring, and S. Weed. 1973. Multiple-stage procedures for drug screening. Biometrics 29 (2):293–300. doi:10.2307/2529393.
   PubMed Web of Science ®Google Scholar
• Scrucca, L. 2017. On some extensions to GA package: Hybrid optimisation, parallelisation and islands evolution. The R Journal 9 (1):187–206. doi:10.32614/RJ-2017-008.
   Google Scholar
• Shim, H., K. Kim, J. Hwang, W. Bae, S. Ryu, Y. Park, T. Nam, I. Chung, and S. Cho. 2016. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. Cancer Chemotherapy and Pharmacology 77 (3):605–612. doi:10.1007/s00280-016-2973-2.
   PubMed Web of Science ®Google Scholar
• Shimura, M., K. Maruo, and M. Gosho. 2018. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early. Pharmaceutical Statistics 17 (5):400–413. doi:10.1002/pst.1859.
   PubMed Web of Science ®Google Scholar
• Siegmund, D. 1978. Estimation following sequential tests. Biometrika 65 (2):341–349. doi:10.2307/2335213.
   Web of Science ®Google Scholar
• Simon, R. 1989. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10 (1):1–10. doi:10.1016/0197-2456(89)90015-9.
   PubMedGoogle Scholar
• Troendle, J., and K. Yu. 1999. Conditional estimation following a group sequential clinical trial. Communications in Statistics - Theory and Methods 28 (7):1617–1634. doi:10.1080/03610929908832376.
   Web of Science ®Google Scholar
• Tsai, W., Y. Chi, and C. Chen. 2008. Interval estimation of binomial proportion in clinical trials with a two-stage design. Statistics in Medicine 27 (1):15–35. doi:10.1002/sim.2930.
   PubMed Web of Science ®Google Scholar
• Tsiatis, A., G. Rosner, and C. Mehta. 1984. Exact confidence intervals following a group sequential test. Biometrics 40 (3):797–803. doi:10.2307/2530924.
   PubMed Web of Science ®Google Scholar